Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
about
Targeting DNA Replication Stress for Cancer TherapyHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerPARP inhibitors in the management of breast cancer: current data and future prospectsPARP inhibitors and moreEffect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitroComplementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line.Rad51 supports triple negative breast cancer metastasis.Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.Regulation and roles of Cdc7 kinase under replication stress.Base excision repair defects invoke hypersensitivity to PARP inhibition.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.BRCA1 pathway function in basal-like breast cancer cells.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.UbcH7 regulates 53BP1 stability and DSB repairEnhanced killing of SCC17B human head and neck squamous cell carcinoma cells after photodynamic therapy plus fenretinide via the de novo sphingolipid biosynthesis pathway and apoptosisTargeting the DNA repair pathway in Ewing sarcomaAutoimmune response to PARP and BRCA1/BRCA2 in cancerBCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.Addicted to PAR? A closer look at PARP inhibitor sensitivity.Predicting PARP inhibitor sensitivity and resistance.PARI overexpression promotes genomic instability and pancreatic tumorigenesis.Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining.PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD MyoblastsNew developments in the treatment of ovarian cancer--future perspectives.The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.Reprogramming cellular events by poly(ADP-ribose)-binding proteinsPARP inhibitors in cancer therapy: an update.Resistance to PARP-Inhibitors in Cancer Therapy.Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Discussion of PARP inhibitors in cancer therapy.Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.New therapeutic perspectives in CCDC6 deficient lung cancer cells.
P2860
Q26739923-4D813F30-B41F-4980-8CA4-32F67C63C5A3Q26783551-664C2E2E-D1F4-4620-A8FE-8C4EB16F8931Q26798352-61EFE5FC-B15F-4E15-B615-D5983BC10A4EQ27027014-0783F433-EA4C-4835-BA84-90D193748E00Q27853018-52389D0A-F7D8-4080-8026-E720814D9AF2Q27853152-31BDF991-0A1A-47DB-A7CB-C9CFCCE0BD8BQ33859206-FEFC5197-F6E0-4354-AF17-92EAFEE2B7E8Q33917622-2DC79512-A330-4FF3-8A90-91DD671A5C52Q33917649-15323218-2D21-49E5-BED7-CA99220E6773Q33953075-FAA8B898-D0D2-4BCD-9660-ED27B4D7AC01Q34053881-5CC9A2C9-57F4-48FD-AA9B-F08F12EA34FEQ34103963-4D0E8E36-E438-444F-B035-B7CF6A339F84Q34297981-2E2415CB-F793-437B-B0AE-C08888824F6BQ34501206-2254F53A-F436-4D8A-9204-39EC1D697398Q34709157-EE2E6997-1DB5-46BB-B5EF-4C696A2B01AAQ35247192-8A20777C-B675-403F-9DD7-2A9D47E3F2F7Q35283099-40F2B3DA-5704-49FE-B5C0-38163E68A9B0Q35793861-264E8878-D352-47C3-A3BA-D23BA20C10F8Q35909731-6A14CB50-B61B-4167-ACAE-F8C2DEE11404Q36203280-C653F397-0769-4559-A52D-C5EECEBF1BCAQ36245791-9FAEBD50-0ECE-44C0-9D85-1C6B1525A49BQ36426473-C29E7759-91B1-4979-B99F-7C716F881E36Q36472222-7418B848-C1C2-449D-8A5F-634BAF4F5B71Q36778113-AF9EC816-3F97-47D4-BDEE-7F94EA14DECCQ37169959-B873FCED-3E94-4A44-A165-0B02D891F09EQ37240662-C6A49532-BA16-4DC5-86AB-CBCFF426CECBQ37299259-5E8C8786-BDE5-4A00-A3F4-52FB52E6139BQ37312029-F6093A15-038B-490B-83B9-A0AFCC7910E0Q37332487-93715DA8-AA81-48FD-A99F-B3C208C6B65DQ37381571-2FFAB5AF-11E3-4DB7-A096-DF7B8DA48F9BQ37475476-F32F3A5F-79CC-476D-A6F2-3B783805267EQ37668511-59240200-A39F-4763-8008-17E25D197185Q38069879-DEE9A76F-38FB-4A7A-8092-F36E99283C8CQ38078993-20914880-D6F8-4276-9A41-CA80358A4313Q38085600-EB4253AD-416B-4C7F-BFB9-9D7971F6FF18Q38160737-34187DA7-70E0-4067-8FFC-4A9ABD60E094Q38163013-71B833FA-91B4-4257-9297-62D0C228EDC0Q38435441-DE2B8985-56DE-4D60-B68F-CF38CC920525Q38798706-C54C7EB5-9D9E-4F24-B2AA-57E7AA518FF6Q38949133-FC30D87A-C7E0-467B-ADBA-3758A14A8DFB
P2860
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@ast
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@en
type
label
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@ast
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@en
prefLabel
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@ast
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@en
P2093
P2860
P50
P356
P1433
P1476
Evaluation of candidate biomar ...... to PARP-1 inhibitor treatment
@en
P2093
Gabriela Korinkova
Kamila Wolanin
Lenka Oplustilova
Mark J O'Connor
Martin Mistrik
P2860
P304
P356
10.4161/CC.22026
P577
2012-09-14T00:00:00Z